In Part I, we explored why cognitive assessment has become essential in MS clinical trials, examining the disconnect between physical and cognitive disability, the limitations of traditional outcome measures, and the heterogeneous cognitive profile that characterizes MS. In Part II, we examine how computerized cognitive assessment addresses these measurement challenges and what this means for the future of MS drug development.
The Signant SmartSignals™ CDR System addresses these measurement needs through principles established over four decades of neuroscience research. Automated computerized testing captures reaction time with millisecond precision—essential for detecting subtle changes in processing speed that paper-based tests miss. Multiple parallel forms enable repeated assessment without practice effects that can obscure true treatment responses. Automated scoring eliminates inter-rater variability that plagues clinician-administered scales.
A 2011 longitudinal validation study in 43 patients with relapsing-remitting MS demonstrated the CDR System's psychometric properties in this population. The battery assessed Power of Attention, Continuity of Attention, Quality of Working Memory, Quality of Episodic Memory, and Speed of Memory through computerized tasks administered repeatedly over 24 months. Baseline scores revealed large impairments in visual information processing speed and attention compared to normative data, with moderate impairment in complex information processing. Working memory and episodic memory accuracy remained relatively preserved, consistent with the MS cognitive profile, where processing speed and attention show more severe deficits than memory encoding.
The CDR measures demonstrated strong correlations with DSST and PASAT established MS cognitive tests and showed robust relationships with disability measured by EDSS and MSFC. Power of Attention correlated 0.62 with baseline EDSS, while the CDR composite score correlated 0.76 with EDSS at 24 months. These correlations demonstrate that computerized attention and processing speed measures capture disability-relevant cognitive function while offering advantages over traditional assessments.
Test-retest reliability proved excellent, essential for detecting change in clinical trials. The automated administration by non-specialists, brief completion time (under 30 minutes), and availability of multiple language versions and parallel forms support multinational trial implementation. The battery's comprehensive domain coverage, spanning focused and sustained attention, working memory, episodic memory, and motor speed, provides cognitive profiling beyond what single-test approaches like SDMT alone can achieve.
Modern MS trials increasingly include cognitive outcomes. Primary progressive MS studies evaluate cognitive performance alongside clinical endpoints, MRI lesions, physical function, and quality of life. Relapsing MS trials assess processing speed changes using instruments ranging from SDMT alone to comprehensive batteries. Progressive MS trials, seeking treatments that slow neurodegeneration, require sensitive measures capable of detecting subtle cognitive changes before severe physical disability develops.
The CDR System's bidirectional sensitivity, proven through decades of phase I safety studies enables detection of both cognitive enhancement and impairment. This capability matters when evaluating novel mechanisms. If a BTK inhibitor or remyelinating agent improves specific cognitive domains, comprehensive batteries reveal those benefits. If a new immunomodulator produces unexpected cognitive side effects, early detection protects patient safety and informs dose optimization.
Digital adaptation expands assessment accessibility. The validated web-based CDR System maintains millisecond precision while enabling home-based testing critical for decentralized trial designs and for reaching patients with mobility limitations. Recent research demonstrates that smartphone and tablet adaptations of cognitive tests, when properly validated, show strong psychometric properties. The CDR System's evolution to web-based delivery preceded this digital transformation, establishing validation data supporting remote administration while preserving measurement fidelity.
Composite outcome strategies, increasingly employed in MS trials, combine cognitive assessment with functional, motor, and quality-of-life measures. The CDR System integrates naturally into these approaches. Its domain-specific scores enable analyses correlating cognitive changes with MRI biomarkers, neurofilament levels, patient-reported outcomes, and physical performance measures. When combined with SDMT as a processing speed anchor, CDR assessments provide broader cognitive coverage supporting exploratory analyses of domain-specific treatment effects.
Current MS drug development pipelines include multiple approaches targeting neurodegeneration, remyelination, and neuroprotection. The 2024 update on clinical trials in progressive MS highlighted both modest but meaningful successes from immunomodulatory approaches approved since 2014 and challenges ahead. New drug classes like BTK inhibitors approach trial completion. Neuroprotective compounds that succeeded in preclinical models await validation in larger studies. Stem cell therapies, gene therapies targeting specific mutations, and novel anti-inflammatory approaches all require cognitive outcome measures sensitive enough to detect treatment effects.
Trial design innovations seek greater efficiency. Adaptive designs, enrichment strategies using biomarkers, and platform trials testing multiple interventions simultaneously all demand robust outcome measures. Cognitive endpoints must show sufficient sensitivity to detect meaningful change within feasible sample sizes and trial durations yet demonstrate specificity adequate for regulatory acceptance. The tension between comprehensive assessment and participant burden drives refinement of cognitive batteries seeking optimal combinations of tests that maximize information while minimizing fatigue.
The recognition that MS encompasses diverse phenotypes, including cognitive-predominant subtypes, suggests personalized approaches to treatment and outcome assessment. Patients with primary attention deficits may require different cognitive measures than those with predominant memory impairment or executive dysfunction. Trials enriched for specific cognitive phenotypes need assessment tools capable of detecting domain-specific changes rather than relying solely on global processing speed measures.
The concept of "no evidence of disease activity" in MS trials traditionally encompassed relapse rate, EDSS progression, and MRI activity. MSOAC analyses demonstrate this composite's significant shortcoming: it misses an important source of MS-related disability cognitive decline. Future disease-modifying therapy trials that claim to fully assess MS-related disability must include cognition. Without cognitive outcomes, trials cannot determine whether treatments preserve the functions that enable employment, complex task performance, and independent living.
The CDR System's extensive normative database, accumulated from thousands of participants across therapeutic areas over 40 years, supports the interpretation of MS-specific findings within broader cognitive aging and pharmacological contexts. This database enables benchmarking cognitive performance against age-matched controls, comparison with other neurological populations, and contextualization of treatment effects within the system's established drug sensitivity profile.
Integration with emerging biomarkers enhances cognitive assessment utility. Correlations between CDR measures and cortical atrophy, grey matter volume, thalamic damage, and specific white matter tract integrity inform a mechanistic understanding of cognitive deficits. When trials combine cognitive outcomes with advanced MRI techniques, plasma neurofilament levels, or other biomarkers, the resulting datasets illuminate relationships between neurobiological changes and functional outcomes, advancing both trial interpretation and disease understanding.
For patients with MS, cognitive impairment often defines quality of life more than physical disability. A recent survey of patients and advocacy organizations consistently emphasized meaningful cognitive assessment as a priority for clinical trials. Patients want treatments evaluated not just for their impact on relapses and walking, but for their effects on thinking speed, concentration, memory, and the mental capacities that enable them to work, maintain relationships, and live independently.
The CDR System addresses this imperative through design aligned with MS cognitive pathophysiology: automated assessment of processing speed and attention, domain-specific profiling revealing selective treatment effects, brief patient-friendly administration reducing participant burden, and validated sensitivity to both impairment and improvement across the disease spectrum. Combined with established measures like SDMT, comprehensive batteries enable trials to capture cognitive changes that matter to patients.
As MS therapeutic development advances toward neuroprotection and repair, cognitive outcomes transition from secondary endpoints to co-primary measures of efficacy. Treatments that slow neurodegeneration must demonstrate benefits on cognitive function not merely fail to harm it. This evolution demands assessment tools demonstrating regulatory-grade validation, proven sensitivity in MS populations, and practical implementation supporting large multicentre trials.
The evidence generation challenge in MS isn't whether cognitive function matters patients, clinicians, and regulators acknowledge its centrality to meaningful outcomes. The challenge is measuring cognitive changes with precision sufficient to detect treatment effects, specificity adequate for regulatory acceptance, and efficiency practical for global trials.
Proof of cognitive benefit, at the speed patients need that's the measurement standard contemporary MS trials demand.
| |
Helen Brooker is a specialist in cognitive test development and aging, with over 18 years of experience in academic and clinical research. She leverages her expertise in neuropsychological assessment, clinical trial delivery, and digital health solutions as a Senior Product Manager at Signant, where she oversees the company's proprietary computerized cognitive test solution. |